Parnaparin sodium is a low-molecular-weight heparin (LMWH), obtained through the depolymerisation of porcine unfractionated heparin (UFH). It is a highly sulphated glycosaminoglycan that is widely used as an injectable anticoagulant. The advent of this class of drugs represented a major medical advance in the prevention and treatment of thromboembolic diseases, as they maintain the same efficacy as unfractionated heparin, but with simplified dosing regimens and reduced side effects.
Parnaparin acts as an antithrombotic and anticoagulant, preventing the formation of new clots and the enlargement of those already present in the blood. It allows natural clot lysis mechanisms to function normally to break up clots that have already formed. Parnaparin binds with antithrombin III and accelerates its activity. By activating antithrombin III, parnaparin preferentially enhances inhibition of coagulation factor Xa and to a lesser extent coagulation factor IIa. Factor Xa catalyses the conversion of prothrombin to thrombin; inhibition of this process results in a decrease in thrombin and, ultimately, the prevention of fibrin clot formation.
- Antithrombotic and anticoagulant therapy in the prophylaxis and treatment of venous thrombosis and its extension
- Prevention of post-operative deep vein thrombosis and pulmonary embolism
- Prevention of coagulation during arterial and heart surgery
- Treatment of deep vein thrombosis and phlebopathies associated with thrombosis